SEC Filings

Form 10-Q
KALA PHARMACEUTICALS, INC. filed this Form 10-Q on 05/10/2018
Document Outline
Entire Document (3226.3 KB)
Subdocument 1 - 10-Q - 10-Q
Page 1 - UNITED STATES
Page 2 - TABLE OF CONTENTS
Page 3 - PART I FINANCIAL INFORMATION
Page 4 - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Page 5 - KALA PHARMACEUTICALS, INC.
Page 6 - KALA PHARMACEUTICALS, INC.
Page 7 - KALA PHARMACEUTICALS, INC.
Page 8 - KALA PHARMACEUTICALS, INC.
Page 9 - KALA PHARMACEUTICALS, INC.
Page 10 - KALA PHARMACEUTICALS, INC.
Page 11 - KALA PHARMACEUTICALS, INC.
Page 12 - KALA PHARMACEUTICALS, INC.
Page 13 - KALA PHARMACEUTICALS, INC.
Page 14 - KALA PHARMACEUTICALS, INC.
Page 15 - KALA PHARMACEUTICALS, INC.
Page 16 - KALA PHARMACEUTICALS, INC.
Page 17 - KALA PHARMACEUTICALS, INC.
Page 18 - Item 2. Management s Discussion and Analysis of Financial Condition and Results of Operations.
Page 19 - Financial Operations Overview
Page 20 - General and Administrative Expenses
Page 21 - Critical Accounting Policies and Significant Judgments and Estimates
Page 22 - Research and Development Expenses
Page 23 - Liquidity and Capital Resources
Page 24 - Net Cash Provided by (Used in) Financing Activities
Page 25 - N/A
Page 26 - Contractual Obligations and Commitments
Page 27 - Item 3.Quantitative and Qualitative Disclosures About Market Risk.
Page 28 - Item 1A Risk Factors
Page 29 - N/A
Page 30 - Our limited operating history may make it difficult for you to evaluate the success of our business
Page 31 - N/A
Page 32 - Raising additional capital may cause dilution to our stockholders, restrict our operations or requir
Page 33 - Risks Related to Product Development
Page 34 - If clinical trials of INVELTYS and KPI 121 0.25% or any other product candidate that we develop fail
Page 35 - If we experience any of a number of possible unforeseen events in connection with our clinical trial
Page 36 - If we experience delays or difficulties in the enrollment of patients in clinical trials, our receip
Page 37 - If serious adverse or unacceptable side effects are identified during the development any of our pro
Page 38 - We may expend our limited resources to pursue a particular product candidate or indication and fail
Page 39 - N/A
Page 40 - If we are unable to establish sales, marketing and distribution capabilities or enter into sales, ma
Page 41 - We face substantial competition, which may result in others discovering, developing or commercializi
Page 42 - If our contracted manufacturing facilities experience production issues for any reason, we may be un
Page 43 - Even if we are able to commercialize INVELTYS, KPI 121 0.25% or any other product candidate that we
Page 44 - Product liability lawsuits against us could divert our resources and could cause us to incur substan
Page 45 - We contract with third parties for the manufacture of INVELTYS and KPI 121 0.25% for commercializati
Page 46 - We may enter into collaborations with third parties for the development or commercialization of our
Page 47 - N/A
Page 48 - If we are not able to establish collaborations, we may have to alter our development and commerciali
Page 49 - Risks Related to Our Intellectual Property
Page 50 - Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecut
Page 51 - We may become involved in lawsuits to protect or enforce our patents or other intellectual property,
Page 52 - inter partes
Page 53 - INVELTYS, KPI 121 0.25% and certain aspects of our MPP technology are protected by patents exclusive
Page 54 - If we fail to comply with our obligations in our intellectual property licenses and funding arrangem
Page 55 - We may not be able to protect our intellectual property and proprietary rights throughout the world.
Page 56 - Intellectual property litigation or other legal proceedings relating to intellectual property could
Page 57 - If the FDA does not conclude that INVELTYS and KPI 121 0.25% satisfy the filing and approval require
Page 58 - Failure to obtain marketing approval in foreign jurisdictions would prevent our product candidates f
Page 59 - N/A
Page 60 - Under the CURES Act and the Trump Administration s regulatory reform initiatives, the FDA s policies
Page 61 - N/A
Page 62 - Recently enacted and future legislation may affect our ability to commercialize and the prices we ob
Page 63 - N/A
Page 64 - If we or any third party manufacturers we engage in the future fail to comply with environmental, he
Page 65 - We are subject to anti corruption laws, as well as export control laws, customs laws, sanctions laws
Page 66 - We might not be able to utilize a significant portion of our net operating loss carryforwards and re
Page 67 - We expect to expand our development, regulatory and manufacturing capabilities and potentially imple
Page 68 - An active trading market for our common stock may not be sustained.
Page 69 - Sale of a substantial number of shares of our common stock into the market could cause the market pr
Page 70 - We are an emerging growth company, and the reduced disclosure requirements applicable to emerging gr
Page 71 - Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable futur
Page 72 - Repurchase of Shares or of Company Equity Securities
Page 73 - Item 6. Exhibits
Page 74 - SIGNATURES
Subdocument 2 - EX-31.1 - EX-31.1
Page 1 - N/A
Subdocument 3 - EX-31.2 - EX-31.2
Page 1 - N/A
Subdocument 4 - EX-32.1 - EX-32.1
Page 1 - N/A
Subdocument 5 - EX-32.2 - EX-32.2
Page 1 - N/A
XBRL Item - EX-101.INS - EX-101.INS (What's this?)
XBRL Item - EX-101.SCH - EX-101.SCH (What's this?)
XBRL Item - EX-101.CAL - EX-101.CAL (What's this?)
XBRL Item - EX-101.DEF - EX-101.DEF (What's this?)
XBRL Item - EX-101.LAB - EX-101.LAB (What's this?)
XBRL Item - EX-101.PRE - EX-101.PRE (What's this?)
XBRL Viewer